Biography

Faculty Profile: https://works.bepress.com/subash-jonnalagadda/

Website: http://users.rowan.edu/~jonnalagadda/

Education:
BS (Chemistry), Pondicherry University, India
MS (Chemistry), University of Hyderabad, India
PhD (Organic Chemistry), Purdue University
Postdoctoral (Organic Chemistry), University of Pennsylvania
Postdoctoral (Medicinal Chemistry), University of Minnesota

Research Expertise:
Organic & Medicinal Chemistry | Organoboron Chemistry | Alternate Energy Materials

Medicinal Chemistry: We have been developing novel aza- and bora-heterocyclic compounds and betulin-based natural product derivatives as anti-cancer agents. In collaboration with Rowan School of Osteopathic Medicine, we have also identified few Withaferin-serotonin conjugates as potential therapeutic options for the treatment of Alzheimers’ Disease.

Value Added Chemicals from Biomass: Recent efforts in this area have included the development of new protocols for the effective conversion of biomass derived cellulosic materials into chemicals such as hydroxymethyl furfural and furan dicarboxylic acid for applications as bio-based polymers.

Honors and Awards:
Rowan University Wall of Fame Teaching Award, 2013, 2016
Eli Lilly International Graduate Scholar, 2000-2005, Purdue University

Member of:
American Chemical Society (www.acs.org)

Recent Publications:

Al-Odat, O. S.; Suskil, M. V.; Chitren, R.; Elbezanti, W. O.; Budak-Alpdogan, T.; Jonnalagadda, S. C.; Pandey, M. K. “Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma” Frontiers in Pharmacology, 2021, 12, 1716-1728

Suskil, M. V.; Sultana, K. N.; Elbezanti, W. O.; Al-Odat, O. S.; Chitren, R.; Tiwari, A. K.; Challagundla, K. B.; Srivastava, S. K.; Jonnalagadda, S. C.; Budak-Alpdogan, T.; Pandey, M. K. “Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma” Intl. J. Mol. Sci., 2021, 22, 5707-5724

Kale, V. P.; Habib, H.; Chitren, R.; Patel, M.; Pramanik, K. C.; Jonnalagadda, S. C.; Challagundla, K.; Pandey, M. K. “Old drugs, new uses: Drug repurposing in hematological malignancies” Seminars in Cancer Biology, 2021, 68, 242-248.

Solano, L. N.; Nelson, G. L.; Ronayne, C. T.; Jonnalagadda, S.; Jonnalagadda, S. K.; Kottke, K.; Chitren, R.; Johnson, J. L.; Pandey, M. K.; Jonnalagadda, S. C.; Mereddy, V. R. “Synthesis, in vitro, and in vivo evaluation of novel N-phenylindazolyl diarylureas as potential anti-cancer agents” Scientific Reports 2020, 10, 17969.

Hossian, A. K. M. N.; Jois, S. D.; Jonnalagadda, S. C.; Mattheolabakis, G. “Nucleic Acid Delivery with α-Tocopherol-Polyethyleneimine-Polyethylene Glycol Nanocarrier System” Intl. J. Nanomedicine, 2020, 15, 6689-6703.

Jonnalagadda, S. K.; Weilenberg, K.; Ronayne, C. T.; Jonnalagadda, S.; Kiprof, P.; Jonnalagadda, S. C.; Mereddy, V. R. "Synthesis and Biological Evaluation of Arylphosphonium-Benzoxaborole Conjugates as Novel Anticancer Agents" Bioorg. Med. Chem. Lett. 2020, 30, 127259.

Fultang, N.; Illendula, A.; Chen, B.; Wu, C.; Jonnalagadda, S. C.; Baird, N.; Klase, Z.; Peethambaran, B. (2019) Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity. PLOS ONE 14:e0217789.

Mereddy, G. R.; Chakradhar, A.; Rutkoski, R. M.; Jonnalagadda, S. C. (2018) Benzoboroxoles: Synthesis and applications in medicinal chemistry.  J. Organomet. Chem. 865:12-22.